OMEPRAZOLE SODIUM

Omeprazole Sodium is used to treat GERD, peptic ulcers, Zollinger-Ellison syndrome, and similar acid-related condition.
Omeprazole Sodium is used as an anttiulcerative.
Omeprazole Sodium is used anti Ulceratives

CAS Number: 95510-70-6 
EC Number: 623-285-9
MDL Number:MFCD01939422
Chemical name (IUPAC): sodium 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazol-1-ide 
Chemical Formula: C₁₇H₁₈N₃NaO₃S 
Molecular Weight: Average ~367.4 g/mol (monoisotopic ~367.10) 

SYNONYMS:
aomeilazuona, OMEPRAZOLE SODIUM, Omeprazole, sodium salt, Omeprazole Sodium hydrate, CEP grade Omeprazole sodium, Omeprazole sodium USP/EP/BP, Omeprazole Sodium Monohydrate, Omeprazole sodium salt hydrate, Omeprazole powder/pellets/sodium, Omeprazole Sodium, sodium 5-methoxy-2-[(RS)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl]-1H-benzimidazole monohydrate, sodium 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]benzimidazol-1-ide, aomeilazuona, OMEPRAZOLE SODIUM, Omeprazole, sodium salt, Omeprazole Sodium hydrate, Omeprazole sodium USP/EP/BP, CEP grade Omeprazole sodium, Omeprazole Sodium Monohydrate, Omeprazole sodium salt hydrate, Omeprazole powder/pellets/sodium, Omeprazole Sodium, 10 mM in DMSO, OMEPRAZOLE SODIUM, 95510-70-6, Losec Sodium, H 168/68 sodium, Omeprazole (as sodium), KV03YZ6QLW, H-168/68 SODIUM, 623-285-9, Omeprazole sodium [USAN], 95510-70-6 (sodium), Andra, Omeprazole sodium (USAN), (s)-omeprazole sodium, 1H-Benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-, sodium salt, Sompraz, 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole, sodium salt, sodium 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, UNII-KV03YZ6QLW, 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]benzimidazole, sodium salt, Losec sodium (TN), Esomeprazole sodium (Nexium), OMEPRAZOLE SODIUM [JAN], CHEMBL2105294, SCHEMBL29512856, SCHEMBL30349275, CHEBI:31934, OMEPRAZOLE SODIUM [MART.], RYXPMWYHEBGTRV-UHFFFAOYSA-N, HMS3651E16, HMS5080C20, HMS5085C09, OMEPRAZOLE SODIUM [WHO-DD], BCP23377, Esomeprazole sodium (Nexium I.V.), AC-403, s5658, AKOS024255604, BCP9000660, OMEPRAZOLE SODIUM [EP MONOGRAPH], BCP0726000228, SW219428-1, D01207, D70375, AB01274809-01, Q27282459, sodium 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-3aH-benzimidazole, 5-Methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methane]sulfinyl}-1-sodio-1H-1,3-benzodiazole, H 168/68 SODIUM, OMEPRAZOLE (AS SODIUM), OMEPRAZOLE SODIUM

Omeprazole sodium is the sodium salt form of omeprazole, belonging to the proton pump inhibitor (PPI) drug class.
Unlike the free base omeprazole, which is poorly soluble in water, Omeprazole Sodium is more soluble and stable, making it particularly useful for intravenous formulations and faster-acting preparations.

Marketed under several trade names, including Prilosec and Losec, Omeprazole Sodium is classified as a proton pump inhibitor (PPI).
This drug targets the H+/K+ ATPase enzyme found in the parietal cells of the stomach lining, effectively reducing the production of stomach acid.

Omeprazole Sodium is prescribed for a range of indications including gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome, among others.
Research institutions across the globe have conducted extensive studies to explore the efficacy and safety profile of Omeprazole Sodium, making it one of the most researched and prescribed medications in its category.

Omeprazole Sodium is a small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
Omeprazole Sodium is the sodium salt form of omeprazole, which is a proton pump inhibitor and suppresses gastric acid secretion.
Omeprazole Sodium is a metabolism-dependent inhibitor (MDI) of CYP2C19.

Omeprazole sodium (H 16868 sodium), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders.
Omeprazole Sodium shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM.
Omeprazole Sodium also inhibits growth of Gram-positive and Gram-negative bacteria.

Omeprazole Sodium is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
Omeprazole Sodium is a white or almost white, hygroscopic powder.
Omeprazole Sodium is the salt analogue of Omeprazole (O635000), which binds covalently to proton pump.

Omeprazole Sodium is a member of benzimidazoles and a sulfoxide.
Omeprazole Sodium is the sodium salt form of omeprazole, which is a proton pump inhibitor and suppresses gastric acid secretion.

USES and APPLICATIONS of OMEPRAZOLE SODIUM:
Omeprazole Sodium is a well-established treatment for various acid-related gastrointestinal disorders.
Omeprazole Sodium's mechanism of action involves the inhibition of the H+/K+ ATPase enzyme, leading to a significant reduction in gastric acid production.

Omeprazole Sodium is generally well-tolerated, but it is not without its side effects and contraindications.
Furthermore, Omeprazole Sodium's efficacy can be influenced by interactions with other medications.
Therefore, Omeprazole Sodium is essential for patients to consult their healthcare providers to tailor the treatment to their specific needs and circumstances.

With appropriate use, Omeprazole Sodium can offer substantial relief from the discomfort associated with excessive gastric acid production, thereby improving the quality of life for many patients.
Omeprazole sodium is widely prescribed in gastroenterology for conditions caused by excess stomach acid.

Omeprazole Sodium is especially used for intravenous administration, for patients who cannot take oral capsules (e.g., ICU patients, post-surgery).
Omeprazole Sodium is a widely recognized pharmaceutical agent used primarily in the management of various conditions associated with excessive gastric acid production.

The mechanism of action of Omeprazole Sodium is relatively straightforward yet highly effective.
As a proton pump inhibitor, Omeprazole Sodium works by irreversibly binding to the H+/K+ ATPase enzyme on the surface of gastric parietal cells.
This binding action inhibits the final step of acid production in the stomach, thereby significantly reducing gastric acidity.

The drug's action helps to alleviate symptoms associated with acid-related disorders such as heartburn, difficulty swallowing, and persistent cough.
Moreover, Omeprazole Sodium allows for the healing of erosive esophagitis and other injuries caused by stomach acid.

Omeprazole Sodium's ability to maintain a basal acid level over an extended period makes it a valuable treatment option for chronic conditions.
Administration of Omeprazole Sodium is relatively simple and can be tailored to suit individual patient needs.
The medication is available in various forms, including delayed-release capsules, tablets, and oral suspensions, which makes Omeprazole Sodium adaptable for different patient preferences and tolerances.

Typically, the standard dosage ranges from 20 mg to 40 mg per day, taken before a meal, usually in the morning.
For patients with more severe conditions or those not responding to the standard dosage, higher doses or prolonged treatment durations may be recommended.

The onset of action for Omeprazole Sodium is generally within one hour of administration, with peak effects occurring within two hours.
However, Omeprazole Sodium may take several days of consistent use for patients to experience full relief of symptoms.
For short-term conditions like acute GERD, a treatment duration of four to eight weeks is often sufficient, while chronic conditions may require longer or even continuous therapy.

Originally approved by the FDA in 1989, Omeprazole Sodium is a proton-pump inhibitor, used to treat gastric acid-related disorders.
These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid.

Omeprazole Sodium was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs 6.
Omeprazole Sodium is generally effective and well-tolerated, promoting its popular use in children and adults

Pharmacological Use: Omeprazole sodium is the sodium salt of omeprazole, a proton-pump inhibitor (PPI).
Omeprazole Sodium irreversibly inhibits the H⁺/K⁺-ATPase in stomach lining, effectively reducing gastric acid secretion.
Omeprazole Sodium is used to treat GERD, peptic ulcers, Zollinger-Ellison syndrome, and similar acid-related condition.

Omeprazole Sodium inhibits gastric secretion.
Omeprazole Sodium is used as an anttiulcerative.
Omeprazole Sodium is used anti Ulceratives

-Key uses of Omeprazole Sodium include:
Gastroesophageal Reflux Disease (GERD) – Omeprazole Sodium reduces acid reflux and related symptoms like heartburn.
Peptic and Duodenal Ulcers – Omeprazole Sodium promotes ulcer healing by lowering stomach acidity.

Zollinger–Ellison Syndrome – Omeprazole Sodium controls excessive gastric acid caused by gastrin-producing tumors.
Erosive Esophagitis – Omeprazole Sodium protects esophagus lining from acid-induced damage.
Stress Ulcer Prophylaxis – in critically ill patients where gastric bleeding risk is high.

NSAID-Induced Ulcers –Omeprazole Sodium helps prevent stomach damage in patients on long-term NSAIDs.
Helicobacter pylori Eradication – Omeprazole Sodium isused in combination therapy with antibiotics to reduce bacterial survival in acidic conditions.

ADVANTAGES of OMEPRAZOLE SODIUM:
Acid suppression onset within ~1 hour; maximal ~2 hours; effect lasts up to ~72 hours
First clinically useful PPI, well tolerated in both children and adults

Omeprazole sodium is a member of benzimidazoles and a sulfoxide.
Omeprazole Sodium is the sodium salt form of a benzimidazole with selective and irreversible proton pump inhibitor activity.

In the acidic compartment of parietal cells, Omeprazole Sodium is protonated and converted into the active achiral sulfenamide; the active sulfenamide forms one or more covalent disulfide bonds with the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting its activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production.
H+/K+ ATPase is an integral membrane protein of the gastric parietal cell.